en POLSKI
eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank


Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
1/2006
vol. 44
 
Share:
Send email
Share:
abstract:

ORIGINAL ARTICLE
Leflunomide in treatment of RA patents preliminary estimation of therapeutical efficiency and side effects

Maria Rell-Bakalarska
,
Janusz Jaworski
,
Lidia Rutkowska-Sak
,
Małgorzata Wieczorek
,
Małgorzata Kwiatkowska
,
Ewa Klimczak
,
Bożena Kowalczuk
,
Krzysztof Wojciech Rell

RU 2006; 44, 1: 19-25
Online publish date: 2006/02/15
View full text Get citation
 
In the preliminary estimation there were studied efficiency and safety of therapy leflunomid in patients with RA. The drug was given p. o. to a group of 158 patients (150 females and 8 males) for 3 days 100 mg/24 h, and then again 20 mg/24 h.
The age of patients varied between 19-78 (average age was 55 years), with average duration time of the disease 10 years and 2 months. All of the patients were previously unsuccessfully treated with other DMARDS. All of the patients had high activity of disease estimated by DAS 28 ≥5.1 61.4% of patients were treated with long-term glicocorticosteroids. Time of trial was scheduled for 6 months. The therapeutical effect was initially estimated on the basis of a group of 43 patients who took the medicine for 91-120 days.
Good and average therapeutical efficiency of treatment was observed in 76.73% of patients. Efficiency was expressed by lowering DAS 28 by 0.6-1.2 in a group of 11.62% of patients and 1.2 in a group of 65.11% of patients. In a group of 3.79% of patients the treatment was stopped because of complete lack of therapeutical effect.
Frequency of side effects was initially estimated in a group of 158 patients.
Treatment was interrupted in the group of 8.86% of patients because of such side effects as: diarrheas, elevation of transaminazes, leukopenia and trombocytopenia, skin changes and dizziness. Observations are continued. Preliminary results of observations allow for positive evaluation of treatment with leflunomid in RA patients.
keywords:

rheumatoid arthritis, diseases modifying antirheumatic drugs, therapeutical effect
EVENTS/KONFERENCJE
BOOKS/KSIĄŻKI



Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.